Recombinant Human IL-13 Protein (HEK293), C-GST

Interleukin-13 (IL-13) is a crucial cytokine involved in various immunological processes, primarily associated with the regulation of allergic responses and airway inflammation. As a product of activated T-helper 2 (Th2) cells, IL-13 plays a pivotal role in the pathogenesis of asthma and other allergic diseases by promoting mucus production, airway hyperresponsiveness, and the proliferation of tissue eosinophils. Research into IL-13 has increased significantly due to its potential as a therapeutic target for treating allergic conditions and inflammatory diseases. Recombinant IL-13 proteins are valuable tools in researching its biological functions and mechanisms of action, facilitating advancements in understanding Th2-mediated polarization in immune responses. These studies aim to delineate the role of IL-13 in disease states, investigate its signaling pathways, and analyze the potential for blocking IL-13's activity to alleviate symptoms in asthma and other related diseases. By utilizing IL-13 recombinant proteins, scientists are better equipped to explore the development of novel therapeutic strategies, including monoclonal antibodies and small molecule inhibitors that might disrupt its action, ultimately leading to improved clinical outcomes for patients suffering from Th2-driven pathologies. The ongoing investigation into IL-13 not only enhances our comprehension of its role in immune system regulation but also marks a significant step towards targeted immunotherapies in the realm of allergic and inflammatory diseases.